The work carried out based on the results of the ARVAC protocol won first prize in the Oral presentation category.
With pride and gratitude we tell you that we are part of the team of scientific work professionals that won the first prize in its category entitled: “Immunogenicity and safety of a recombinant protein booster vaccine for SARS-CoV-2 that contains the binding domain to the Spike protein receptor of the virus in its Gamma, Omicron BA.4/5 and bivalent versions in adults previously vaccinated with different vaccination platforms: A randomized phase II, III clinical trial, which was presented at the XXIV Congress of the Argentine Society of Infectious Diseases (SADI), one of the most important events in the field of infectious diseases at the national level.
More information
📧 info.gruposurinvestigacion@gmail.com
Grupo Sur
Departamento de Investigación Clínica del Instituto Médico Platense

Compartir: